HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E.l.f. Cosmetics, CeraVe Skin Care Reign Among US Teens’ Favorite Beauty Brands

Executive Summary

US teens identified e.l.f. Beauty as their No. 1 cosmetics brand and CeraVe as their favorite in skin care in a survey by investment bank Piper Sandler Companies. Respondents, who are spending more on average on core beauty products in 2022, also identified growing preference for “clean” offerings and shopping in Ulta stores.

You may also be interested in...



E.l.f. Continues To Win With Value Pricing, Youth Appeal; 33% Growth In Second Quarter

The firm is targeting 22%-24% net sales growth for the fiscal full year ended 31 March 2023 after reporting its 15th consecutive quarter of growth.

Unilever’s Living Proof To Provide First Look At Revieve AI Haircare Advisor

Living Proof will be first out of the gates with the new AI Haircare Advisor from beauty tech firm Revieve. The digital tool is designed to go beyond modeling hair color and tone effects, leveraging consumer input and selfie to match with hair cleansing, conditioning, and styling products.

Ulta Beauty Achieves 38% Sales Growth In 2021, Predicts 'Normalized' 2022

Ulta’s shop-in-shop partnership with Target Corporation, expansion of its Conscious Beauty platform, and its growing investment in BIPOC-associated brands were among highlights in fiscal 2021, which benefited from comparisons against 2020 when the world locked down under siege by COVID-19.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel